ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients

By exposing laboratory-grown cancer cells to a multitude of different cancer treatments, physicians can select the treatment that best suits the individual patient, Interview with Principal Investigator TICC1, Lars Henrik Jensen, Vejle Hospital, Denmark.

(Onkologisk Tidsskrift, article in in Danish, read it here)

For more information about 2cureX: Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com